MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
The Alathur facility specializes in the production of Cephalosporin antibiotics
EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA
Such combined efficacy (achieving clinical cure and microbiologic cure) of Zaynich is highest ever among all the FDA-approved novel antibiotics developed in the last more than 10 years
The overall clinical efficacy of Zaynich across indications was 98% at the test-of-cure
40th DSIR Foundation Day celebration marks 16 more technology transfers from CSIR to MSMEs
Wockhardt plans to launch Miqnaf in the Indian market in coming few months
MRX-5 is a novel benzoxazole antibiotic developed for the treatment of mycobacteria infections, particularly infections caused by non-tuberculous Mycobacteria
India's bio economy has experienced remarkable growth, skyrocketing from $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
Infections with H. pylori affect over 43 percent of the world’s population with a wide range of gastrointestinal disorders
Subscribe To Our Newsletter & Stay Updated
